Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:VINC

Vincerx Pharma Earnings Date & Estimates

Vincerx Pharma logo
$0.03 0.00 (0.00%)
As of 10/12/2026

Vincerx Pharma is estimated to report earnings on Tuesday, November 10, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Vincerx Pharma

Vincerx Pharma is expected to post earnings of -$8.00 per share. Vincerx Pharma last reported on August 8, 2024, posting -$1.00 per share and beating the -$3.40 consensus estimate. Vincerx Pharma has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$8.00

Recent Track Record

Last Reported
Aug 8, 2024
Last Quarter EPS
-$1.00 (Beat by +$2.40)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Vincerx Pharma Earnings FAQ

Vincerx Pharma (NASDAQ:VINC) is estimated to report earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Vincerx Pharma to post earnings of -$8.00 per share for the quarter.

Vincerx Pharma Earnings Headlines

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 13 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
See More Vincerx Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vincerx Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vincerx Pharma and other key companies, straight to your email.

About Vincerx Pharma

Vincerx Pharma (NASDAQ:VINC) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company’s research programs combine small-molecule therapeutics with antibody-drug conjugates designed to selectively deliver treatment to diseased cells.

Vincerx’s pipeline has included VIP152, an investigational cyclin-dependent kinase 9 inhibitor being studied as a potential treatment for hematologic malignancies and solid tumors, and VIP943, an antibody-drug conjugate targeting CD123 for certain blood cancers. These candidates remain investigational and have not been approved for commercial use.

Vincerx Pharma was founded in 2019 and is based in Palo Alto, California. The company’s operations and clinical development activities have been focused primarily on oncology, with studies conducted through research and clinical networks serving patients in the United States and other regions. Ahmed Hamdy, M.D., has served as a co-founder and chief executive officer.

View Vincerx Pharma Profile
Earnings Tools